”Luteolin offers novel therapeutic regimen in rotenone-induced Parkinson disease via modulation of TNF-α/FXMRP/serotonin/tyrosine hydroxylase signaling pathway”, NJPS, vsk. 40, nro 2, s. 251–262, joulu 2025, doi: 10.54548/.